Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siyu Feng

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Nature Biotechnology|January 7, 2022
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitorsChristopher W Davies, Angela J Oh, Rana Mroue, et al.
Cancer Discovery|March 6, 2026
Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic MutantsCarlos Stahlhut, Anna E Maciag, Kyle A Sullivan, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Genome-wide CRISPR screens identify PTGES3 as a novel AR modulatorHaolong Li, James E Melnyk, Becky Xu Hua Fu, et al.
Science (New York, N.Y.)|June 12, 2025
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interactionDhirendra K Simanshu, Rui Xu, James P Stice, et al.
Nature Genetics|November 5, 2025
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancerHaolong Li, James E Melnyk, Becky Xu Hua Fu, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Nature Biotechnology|January 7, 2022
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitorsChristopher W Davies, Angela J Oh, Rana Mroue, et al.
Cancer Discovery|March 6, 2026
Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic MutantsCarlos Stahlhut, Anna E Maciag, Kyle A Sullivan, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Genome-wide CRISPR screens identify PTGES3 as a novel AR modulatorHaolong Li, James E Melnyk, Becky Xu Hua Fu, et al.
Science (New York, N.Y.)|June 12, 2025
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interactionDhirendra K Simanshu, Rui Xu, James P Stice, et al.
Nature Genetics|November 5, 2025
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancerHaolong Li, James E Melnyk, Becky Xu Hua Fu, et al.
Pageof 5